Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Top-down versus step-up treatment strategies in newly diagnosed Crohn's disease
NL-OMON27896Active, not recruiting
- Sponsor
- Investigator Initiated Study.
- Start
- May 2001
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of infliximab, azathioprine, methotrexate, prednisone, methylprednisolone and 2 more in Crohn's disease (2 arms), sponsored by Investigator Initiated Study. Primary endpoint: Remission at 6 months. Started May 2001; status: active, not recruiting.
02
Drugs
infliximabazathioprinemethotrexateprednisonemethylprednisolone
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON27896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27896.